Long-term follow-up of neointimal coverage of sirolimus-eluting stents--evaluation with optical coherence tomography.

BACKGROUND Late stent thrombosis related to delayed neointimal growth is a major concern after drug-eluting stent (DES) implantation. The time course of neointimal growth and risk factors of uncovered stent struts after sirolimus-eluting stent (SES) was studied using optical coherence tomography (OCT). METHODS AND RESULTS The 60 patients were enrolled and classified into G1 (follow-up period <9 months, n=27), G2 (9-24 months, n=18), and G3 (>25 months, n=15). The time elapsed since SES implantation was associated with a significant increase in mean neointimal area and neointimal thickness, and also with a significant decrease in the number of uncovered stent struts (G1: 14.8%, G2: 11.7%, and G3: 4.1%, P<0.001). However, only 17.6% of implanted SES was completely covered by neointima, even in the G3 period. Small-diameter SES, complex coronary lesions with lipid and calcium content adjacent to stent struts, and diabetes predicted delayed neointimal coverage of SES struts in G1. CONCLUSIONS Neointima inside SES progressively increases after the routine follow-up period, but only a few SES were completely covered at 3 years after implantation. OCT is a useful modality for assessing neointimal formation after SES implantation, and may give important information about the strategy of antiplatelet therapy after DES implantation.

[1]  T. Akasaka,et al.  Safety and usefulness of non-occlusion image acquisition technique for optical coherence tomography. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[2]  David J Cohen,et al.  Stent Thrombosis After Successful Sirolimus-Eluting Stent Implantation , 2004, Circulation.

[3]  P. Serruys,et al.  Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Coronary Stents: Three-Year Results of the RAVEL Trial , 2005, Circulation.

[4]  Hiromasa Otake,et al.  Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. , 2007, European heart journal.

[5]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[6]  Ousa,et al.  A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .

[7]  Patrick W Serruys,et al.  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2004, The Lancet.

[8]  A. Gori,et al.  Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. , 2007, Journal of the American College of Cardiology.

[9]  M. Takano,et al.  Various optical coherence tomographic findings in restenotic lesions after sirolimus-eluting stent implantation. , 2009, International journal of cardiology.

[10]  Eiji Toyota,et al.  Assessment of coronary arterial plaque by optical coherence tomography. , 2006, The American journal of cardiology.

[11]  P. Fitzgerald,et al.  Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial. , 2004, Journal of the American College of Cardiology.

[12]  D. Baim,et al.  Stent Thrombosis in the Modern Era: A Pooled Analysis of Multicenter Coronary Stent Clinical Trials , 2001, Circulation.

[13]  B. Lal,et al.  Hyperglycemia alters PI3k and Akt signaling and leads to endothelial cell proliferative dysfunction. , 2005, American journal of physiology. Heart and circulatory physiology.

[14]  R. Virmani,et al.  Pathology of in-stent restenosis. , 1999, Current opinion in lipidology.

[15]  Fesc,et al.  Safety of Coronary Sirolimus-Eluting Stents in Daily Clinical Practice: One-Year Follow-Up of the e-Cypher Registry , 2006, Circulation.

[16]  Deepak L. Bhatt,et al.  Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. , 2002, Journal of the American College of Cardiology.

[17]  Takashi Akasaka,et al.  Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. , 2007, Journal of the American College of Cardiology.

[18]  J. Tanigawa,et al.  Heavily calcified coronary lesions preclude strut apposition despite high pressure balloon dilatation and rotational atherectomy: in-vivo demonstration with optical coherence tomography. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[19]  David B Matchar,et al.  Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. , 2007, JAMA.

[20]  R. Virmani,et al.  Endothelial cell recovery between comparator polymer-based drug-eluting stents. , 2008, Journal of the American College of Cardiology.

[21]  Eiji Toyota,et al.  Visualization of neointima formation by optical coherence tomography. , 2005, International heart journal.

[22]  A. Cribier,et al.  Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. , 1996, Circulation.

[23]  J. Moses,et al.  Sirolimus-eluting stents vs. standard stents in patients with stenosis in a native coronary artery , 2004 .

[24]  G. Papandreou,et al.  Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent , 2002, Coronary artery disease.

[25]  K. Kent,et al.  Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. , 2008, The American journal of cardiology.

[26]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. , 2006, Journal of the American College of Cardiology.

[27]  M. Pfisterer,et al.  BASKET-LATE INVESTIGATORS, LATE CLINICAL EVENTS AFTER CLOPIDOGREL DISCONTINUATION MAY LIMIT THE BENEFIT OF DRUGELUTING STENTS: AN OBSERVATIONAL STUDY OF DRUG-ELUTING VERSUS BARE-METAL STENTS , 2006 .

[28]  Brett E Bouma,et al.  Optical coherence tomography as a tool for percutaneous coronary interventions , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[29]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. , 2006, Circulation.

[30]  C. Grines,et al.  Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Journal of the American College of Cardiology.

[31]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[32]  Timothy J Gardner,et al.  Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Circulation.

[33]  Wan-Wan Lin,et al.  High Glucose Induces Human Endothelial Cell Apoptosis Through a Phosphoinositide 3-Kinase–Regulated Cyclooxygenase-2 Pathway , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[34]  B. Gersh,et al.  Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement: Results From the PREMIER Registry , 2007 .

[35]  M. Takano,et al.  Late coronary thrombosis in a sirolimus-eluting stent due to the lack of neointimal coverage. , 2006, European heart journal.

[36]  M. Takano,et al.  CorrespondenceResearch CorrespondenceLong-Term Follow-Up Evaluation After Sirolimus-Eluting Stent Implantation by Optical Coherence Tomography: Do Uncovered Struts Persist? , 2008 .

[37]  福家 聡一郎 Impaired endothelial vasomotor function after sirolimus-eluting stent implantation , 2010 .

[38]  Jeffrey L. Anderson,et al.  2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. , 2008, Journal of the American College of Cardiology.

[39]  Patrick Hunziker,et al.  Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. , 2006, Journal of the American College of Cardiology.

[40]  B. Bouma,et al.  Power-efficient nonreciprocal interferometer and linear-scanning fiber-optic catheter for optical coherence tomography. , 1999, Optics letters.